Estrella Immunopharma, Inc.

NasdaqCM:ESLA Stock Report

Market Cap: US$36.2m

Estrella Immunopharma Valuation

Is ESLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ESLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ESLA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ESLA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ESLA?

Key metric: As ESLA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ESLA. This is calculated by dividing ESLA's market cap by their current book value.
What is ESLA's PB Ratio?
PB Ratio49x
BookUS$746.29k
Market CapUS$36.19m

Price to Book Ratio vs Peers

How does ESLA's PB Ratio compare to its peers?

The above table shows the PB ratio for ESLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.7x
LIAN.Y LianBio
0.2xn/aUS$31.4m
LTRN Lantern Pharma
1.2x-3.8%US$33.8m
NLTX Neoleukin Therapeutics
0.4xn/aUS$32.8m
AGE AgeX Therapeutics
5.1xn/aUS$31.5m
ESLA Estrella Immunopharma
49xn/aUS$36.2m

Price-To-Book vs Peers: ESLA is expensive based on its Price-To-Book Ratio (49x) compared to the peer average (1.7x).

Price to Book Ratio vs Industry

How does ESLA's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
ESLA 49.0xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ESLA is expensive based on its Price-To-Book Ratio (49x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is ESLA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ESLA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio49x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ESLA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%